Welcome to our dedicated page for Processa Pharmaceuticals Common news (Ticker: PCSA), a resource for investors and traders seeking the latest updates and insights on Processa Pharmaceuticals Common stock.
Processa Pharmaceuticals, Inc. (symbol: PCSA) is a clinical-stage biopharmaceutical company, founded in October 2017 and headquartered in Hanover, Maryland. The company's mission is to develop products that can significantly improve the survival and quality of life for patients with high unmet medical needs, particularly in the field of oncology.
Processa Pharmaceuticals specializes in the development of Next Generation Chemotherapy (NGC) oncology drug products using a unique 'regulatory science' approach. The company's primary focus is to advance its pipeline of proprietary small molecule oncology drugs. These NGC products are new chemical entities designed to alter the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites, while preserving the original mechanisms of action that kill cancer cells.
The company's current pipeline includes three promising NGC treatments:
- NGC-Capecitabine (NGC-Cap): This therapy involves Capecitabine administered with PCS6422, aiming to enhance efficacy and reduce side effects.
- PCS3117 (NGC-Gemcitabine or NGC-Gem): A novel formulation intended to improve the therapeutic profile of Gemcitabine.
- PCS11T (NGC-Irinotecan or NGC-Iri): Another innovative treatment designed to optimize the benefits of Irinotecan.
Processa Pharmaceuticals is committed to leveraging its expertise in regulatory science to bring these next-generation treatments to market. The company's strategic partnerships and ongoing clinical trials play a crucial role in advancing its mission and providing hope to patients battling cancer. For the latest updates and more information, investors can contact Patrick Lin at plin@processapharma.com.
Rhea-AI Summary
Processa Pharmaceuticals, Inc. presented Phase 1b data on its Next Generation Capecitabine (NGC-Cap) at the AACR Annual Meeting 2024. NGC-Cap showed greater 5-FU exposure and lower side effects compared to monotherapy capecitabine. The study aims to advance NGC-Cap into a Phase 2 trial in breast cancer with FDA support.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.35%
Tags
-
Rhea-AI Summary
Processa Pharmaceuticals, Inc. (PCSA) to present a corporate update at the MedInvest Biotech and Pharma Investor Conference. The focus is on developing advanced chemotherapeutic drugs for cancer patients, with George Ng, CEO, and David Young, President of R&D, participating. The event will take place on April 3-4, 2024, in New York.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.19%
Tags
-
Rhea-AI Summary
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) will present two posters at the American Association for Cancer Research Annual Meeting 2024, showcasing their innovative chemotherapeutic drugs. The posters highlight the advancements in drug safety and efficacy, with promising clinical trial results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.45%
Tags
Rhea-AI Summary
Processa Pharmaceuticals, Inc. (PCSA) will present a corporate update at the 2024 BIO CEO & Investor Conference in New York City. CEO George Ng will discuss the development of chemotherapeutic drugs for cancer patients. Investors can register for the conference and request one-on-one meetings with Mr. Ng.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.47%
Tags
-
Rhea-AI Summary
Processa Pharmaceuticals, Inc. (PCSA) CEO George Ng to present a corporate update at The Winter Wrap-Up MicroCap Rodeo 2024 Virtual Conference. The company focuses on developing chemotherapeutic drugs for cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.43%
Tags
-
Rhea-AI Summary
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Market. The Company's ordinary shares maintained a minimum closing bid price of $1.00 or more for at least 10 consecutive business days, achieving compliance on February 2, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.93%
Tags
Rhea-AI Summary
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) has closed a public offering of 1,555,555 shares of common stock and common warrants, raising $7.0 million in gross proceeds. The offering price per share was $4.50, with the common warrants having an exercise price of $4.50 per share and a term of five years. H.C. Wainwright & Co., LLC acted as the exclusive placement agent for the offering. The registration statement on Form S-1 relating to the offering was declared effective by the SEC on January 26, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.85%
Tags
-
Rhea-AI Summary
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) has announced a public offering of 1,555,555 shares of common stock and common warrants, with a combined public offering price of $4.50 per share. The gross proceeds from the offering are expected to be $7.0 million. The common warrants will have an exercise price of $4.50 per share and a term of five years after their original issuance date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-28.04%
Tags
-
Rhea-AI Summary
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) successfully completed the safety tolerability evaluation in its Phase 1b trial of Next Generation Capecitabine (NGC-Cap), a cancer treatment metabolite. NGC-Cap provides 2-10 times greater exposure to its 5-FU metabolite than capecitabine administration, with better tolerance and positive preliminary efficacy results. The Phase 2 trial in advanced or metastatic breast cancer is based on the Phase 1b data, with NGC-Cap showing potential for improved efficacy and safety over capecitabine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
148.78%
Tags
Rhea-AI Summary
Processa Pharmaceuticals, Inc. announces plans to expand the development of NGC-Cap into the treatment of advanced or metastatic breast cancer. The FDA agrees that existing data and studies can be used to support the Phase 2 breast cancer trial design, making the development a more efficient and straightforward path to approval. The expansion into breast cancer represents a larger market than colorectal cancer, with the potential to differentiate NGC-Cap from existing treatments for breast cancer. Processa plans to initiate the Phase 2 study in the third quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.84%
Tags
FAQ
What is the current stock price of Processa Pharmaceuticals Common (PCSA)?
The current stock price of Processa Pharmaceuticals Common (PCSA) is $0.91 as of November 20, 2024.
What is the market cap of Processa Pharmaceuticals Common (PCSA)?
The market cap of Processa Pharmaceuticals Common (PCSA) is approximately 2.9M.
What is Processa Pharmaceuticals, Inc.?
Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation oncology drug products.
When was Processa Pharmaceuticals founded?
Processa Pharmaceuticals was founded in October 2017.
Where is Processa Pharmaceuticals headquartered?
The company is headquartered in Hanover, Maryland.
What is the mission of Processa Pharmaceuticals?
The mission is to develop products that improve the survival and quality of life for patients with high unmet medical needs.
What does NGC stand for?
NGC stands for Next Generation Chemotherapy.
What are the main products in Processa Pharmaceuticals' pipeline?
The main products include NGC-Capecitabine (NGC-Cap), PCS3117 (NGC-Gemcitabine), and PCS11T (NGC-Irinotecan).
What is the unique approach of Processa Pharmaceuticals?
The company uses a 'regulatory science' approach to develop new chemical entities that enhance the properties of FDA-approved cancer drugs.
How can investors get more information about Processa Pharmaceuticals?
Investors can contact Patrick Lin at plin@processapharma.com for more information.
What recent achievements has Processa Pharmaceuticals made?
Recent achievements include advancements in their NGC treatments and ongoing clinical trials.
Does Processa Pharmaceuticals have any partnerships?
Yes, the company engages in strategic partnerships to advance its mission and bring new treatments to market.
Processa Pharmaceuticals, Inc. Common
Nasdaq:PCSA
PCSA Rankings
PCSA Stock Data
2.94M
2.98M
8.74%
1.49%
2.98%
Biotechnology
Pharmaceutical Preparations
United States of America
HANOVER